EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtVergleichsstudieOpen Access

Dosimetry of [ 177 Lu]Lu-PSMA–Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis

Zachary Ells, Tristan R Grogan, Johannes Czernin, Magnus Dahlbom, Jeremie Calais

Journal of Nuclear Medicine · 2024-08 · 65 (8) · 1264-1271

DOI: 10.2967/jnumed.124.267452 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 03.07.2024. Verfasst von Zachary Ells und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California; and. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Radiometry, Lutetium. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel theranostic approaches using radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) have emerged for treating metastatic castration-resistant prostate cancer. The physical properties and commercial availability of 177Lu make it one of the most used radionuclides for radiopharmaceutical therapy (RPT). In this literature review, we aimed at comparing the dosimetry of the most used [177Lu]Lu-PSMA RPT compounds.

Methods

This was a systematic review and metaanalysis of [177Lu]Lu-PSMA RPT (617, I&T, and J591) dosimetry in patients with prostate cancer. Absorbed doses in Gy/GBq for each organ at risk (kidney, parotid and submandibular glands, bone marrow, liver, and lacrimal glands) and for tumor lesions (bone and nonbone lesions) were extracted from included articles. These were used to estimate the pooled average absorbed dose of each agent in Gy/GBq and in Gy/cycle, normalized to the injected activity (per cycle) used in the VISION (7.4 GBq), SPLASH (6.8 GBq), and PROSTACT trials (5.8 GBq).

Results

Twenty-nine published articles comprising 535 patients were included in the metaanalysis. The pooled doses (weighted average across studies) of [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T were 4.04 Gy/GBq (17 studies, 297 patients) and 4.70 Gy/GBq (10 studies, 153 patients) for the kidney (P = 0.10), 5.85 Gy/GBq (14 studies, 216 patients) and 2.62 Gy/GBq (5 studies, 86 patients) for the parotids (P < 0.01), 5.15 Gy/GBq (5 studies, 81 patients) and 4.35 Gy/GBq (1 study, 18 patients) for the submandibular glands (P = 0.56), 11.03 Gy/GBq (6 studies, 121 patients) and 19.23 Gy/GBq (3 studies, 53 patients) for the lacrimal glands (P = 0.20), 0.24 Gy/GBq (12 studies, 183 patients) and 0.19 Gy/GBq (4 studies, 68 patients) for the bone marrow (P = 0.31), and 1.11 Gy/GBq (9 studies, 154 patients) and 0.56 Gy/GBq (4 studies, 56 patients) for the liver (P = 0.05), respectively. Average tumor doses tended to be higher for [177Lu]Lu-PSMA-617 than for [177Lu]Lu-PSMA-I&T in soft tissue tumor lesions (4.19 vs. 2.94 Gy/GBq; P = 0.26). Dosimetry data of [177Lu]Lu-J591 were limited to one published study of 35 patients with reported absorbed doses of 1.41, 0.32, and 2.10 Gy/GBq to the kidney, bone marrow, and liver, respectively.

Conclusion

In this metaanalysis, there was no significant difference in absorbed dose between [177Lu]Lu-PSMA-I&T and [177Lu]Lu-PSMA-617. There was a possible trend toward a higher kidney dose with [177Lu]Lu-PSMA-I&T and a higher tumor lesion dose with [177Lu]Lu-PSMA-617. It remains unknown whether this finding has any clinical impact. The dosimetry methodologies were strikingly heterogeneous among studies, emphasizing the need for standardization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsRadiometryLutetiumHumansMaleProstatic NeoplasmsGlutamate Carboxypeptidase IIRadioisotopesAntigens, SurfaceProstate-Specific Antigen

Stichwörter der Autor:innen

177LuPSMAdosimetrymetaanalysisprostate cancertheranostics

Substanzen

RadiopharmaceuticalsLutetiumLutetium-177Glutamate Carboxypeptidase IIRadioisotopesFOLH1 protein, humanAntigens, SurfacePluvictoProstate-Specific Antigen

Autor:innen und Institutionen

  • Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California; and.
  • Department of Medicine Statistics Core, David Geffen School of Medicine, UCLA, Los Angeles, California.
  • Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California; and jcalais@mednet.ucla.edu.

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Ells, Z., Grogan, T. R., Czernin, J., Dahlbom, M., & Calais, J. (2024). Dosimetry of [ 177 Lu]Lu-PSMA–Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis. Journal of Nuclear Medicine, 65(8), 1264-1271. https://doi.org/10.2967/jnumed.124.267452

Vancouver

Ells Z, Grogan TR, Czernin J, Dahlbom M, Calais J. Dosimetry of [ 177 Lu]Lu-PSMA–Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis. Journal of Nuclear Medicine. 2024;65(8):1264-1271. doi:10.2967/jnumed.124.267452

BibTeX
@article{Ells2024,
  author = {Ells, Zachary and Grogan, Tristan R and Czernin, Johannes and Dahlbom, Magnus and Calais, Jeremie},
  title = {Dosimetry of [ 177 Lu]Lu-PSMA–Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  volume = {65},
  number = {8},
  pages = {1264--1271},
  doi = {10.2967/jnumed.124.267452}
}
Kostenlos starten →